← All trials
NCT04784416
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 27, 2021
- Primary completion
- Jun 30, 2025
- Completion date
- Nov 30, 2025
- First posted
- Mar 5, 2021
- Last posted
- Aug 3, 2021
- Enrollment
- 125
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- New York UniversityLead sponsor
- National Institutes of Health (NIH)Collaborator
- Harvard UniversityOverall official - principal investigator
- New York UniversityOverall official - principal investigator
- Alzheimer's AssociationCollaborator
- LiteCure LLCCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.